Review of the Efficacy of Individualized Chemotherapy Selected by In Vitro Drug Sensitivity Testing for Patients With Cancer
作者： Patricia Cortazar , Bruce E. Johnson
DOI: 10.1200/JCO.1999.17.5.1625
关键词:
摘要: PURPOSE: The purpose of this study is to review the potential efficacy individualized chemotherapy selected by in vitro drug sensitivity testing (DST) compared with empiric regimens for patients cancer. METHODS: MEDLINE and CANCERLIT were searched articles published (in English) about prospective clinical trials which treated that was use DST. RESULTS: We identified 12 studies examined benefit Five hundred six (33%) mean response rate vitro–selected therapy 27% (range, 10% 100%; n = studies) 18% 0% 7 therapy. (only one randomized) evaluated impact DST on patient survival. Three showed survival 1 4 m...
sci-hub.se 参考文章(42)
F. V. Fossella, Waun Ki Hong, Jin Soo Lee, Management strategies for recurrent non-small cell lung cancer. Seminars in Oncology. ,vol. 24, pp. 455- 462 ,(1997)
Fennelly D, Seidman Ad, Norton L, Baselga J, Hudis Ca, Raptis G, Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience. Oncology. ,vol. 11, pp. 20- 28 ,(1997)
Larry M. Weisenthal, Cindy K. Macaluso, Joye A. Marsden, Patricia L. Dill, A Novel Dye Exclusion Method for Testing in Vitro Chemosensitivity of Human Tumors Cancer Research. ,vol. 43, pp. 749- ,(1983)
Daniel D. Von Hoff, Michael F. Sarosdy, Brian J. Stogdill, James T. Casper, Carey P. Page, Gary M. Clark, John F. Sandbach, Michael T. O'Brien, Douglas E. Mattox, Anatolio B. Cruz, Prospective Clinical Trial of a Human Tumor Cloning System Cancer Research. ,vol. 43, pp. 1926- 1931 ,(1983)
D C Ihde, J L Mulshine, B S Kramer, S M Steinberg, R I Linnoila, A F Gazdar, M Edison, R M Phelps, M Lesar, J C Phares, Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. Journal of Clinical Oncology. ,vol. 12, pp. 2022- 2034 ,(1994) , 10.1200/JCO.1994.12.10.2022
P Eisenberg, M Kane, W A Bierman, J Mortimer, E Genevois, R E Bellet, P M Ravdin, H A Burris, G Cook, Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. Journal of Clinical Oncology. ,vol. 13, pp. 2879- 2885 ,(1995) , 10.1200/JCO.1995.13.12.2879
Frank V Fossella, Jin Soo Lee, Dong M Shin, Maria Calayag, Martin Huber, Roman Perez-Soler, William K Murphy, Scott Lippman, Steven Benner, Bonnie Glisson, None, Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 13, pp. 645- 651 ,(1995) , 10.1200/JCO.1995.13.3.645
James D. Cotelingam, John D. Minna, Adi F. Gazdar, Adi F. Gazdar, Seth M. Steinberg, Daniel C. Ihde, Bimal C. Ghosh, Harvey I. Pass, Ruby Phelps, Bruce E. Johnson, James L. Mulshine, R. Ilona Linnoila, Herbert K. Oie, Gail L. Shaw, Thomas E. Walsh, John C. Nesbitt, Individualized Chemotherapy for Patients with Non-Small Cell Lung Cancer Determined by Prospective Identification of Neuroendocrine Markers and in Vitro Drug Sensitivity Testing Cancer Research. ,vol. 53, pp. 5181- 5187 ,(1993)
Chun-Ming Tsai, Yuh-Min Chen, Mei-Hui Chen, Kuo-Ting Chang, Jeou-Yuan Chen, Reury-Perng Perng, Cytotoxic Effects of Gemcitabine-containing Regimens against Human Non-Small Cell Lung Cancer Cell Lines Which Express Different Levels of p185neu Cancer Research. ,vol. 56, pp. 794- 801 ,(1996)
V Valero, F A Holmes, R S Walters, R L Theriault, L Esparza, G Fraschini, G A Fonseca, R E Bellet, A U Buzdar, G N Hortobagyi, Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. Journal of Clinical Oncology. ,vol. 13, pp. 2886- 2894 ,(1995) , 10.1200/JCO.1995.13.12.2886